Market Data
Market Cap₹26,307.65 Cr.
52W High₹3,735
Current Price₹3,213.3
52W Low₹1,290.05
Down from 52W High14 %
Face Value₹5
Performance
ROCE31.51 %
ROE23.36 %
EPS (TTM)₹9.07
EPS Prev Qtr₹16.09
EPS Last Year₹8.82
EBITDA Qtr₹103.25 Cr.
Book Value₹202
Financial Health
Debt/Equity0.02
Debt/Profit0.09
Total Assets₹1,983.96 Cr.
Dividend Yield0.08 %
Promoter Holding32.66 %
Earning Power25.45 %
Valuation
Stock P/E68.12
Industry P/E33.81
Price to Book15.91
Price to Sales18
Graham Number₹462.98
Key Metrics
Face Value
₹5
About Acutaas Chemicals Ltd
Healthcare · Pharmaceuticals
Acutaas Chemicals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹5. Market cap ₹26,307.65 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company exhibits a high ROCE of 40.4%, indicating efficient use of capital.
- ROE stands at 29.58%, reflecting strong returns generated on shareholders' equity.
- The company has a low debt-to-equity ratio of 0.01, suggesting minimal financial risk.
- Promoter holding is at 32.66%, indicating significant management control and alignment of interests.
Weaknesses
- The P/E ratio of 71.6 suggests that the stock may be overvalued relative to earnings.
- The P/B ratio of 21.11 indicates that the market values the company at a premium over its book value.
- The dividend yield is very low at 0.07%, offering limited income to investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 306.2 | 393.18 | 432.75 | 329.67 |
| ↳ QoQ Growth | - | +28.4% | +10.1% | -23.8% |
| Expenses | 219.27 | 252.35 | 258.87 | 226.43 |
| Operating Profit | 86.92 | 140.83 | 173.88 | 103.25 |
| OPM % | 28.39% | 35.82% | 40.18% | 31.32% |
| Other Income | 9.84 | 4.7 | 11.11 | 1.8 |
| Interest | 0.58 | 0.86 | 1.19 | 1.14 |
| Depreciation | 8.4 | 9.82 | 9.63 | 9.82 |
| EBITDA | 95.32 | 150.65 | 183.51 | 113.07 |
| EBITDA Margin % | 31.13% | 38.32% | 42.41% | 34.3% |
| Profit Before Tax | 96.18 | 144.67 | 183.8 | 103.91 |
| Tax % | 25.29% | 26.58% | 26.94% | 27.83% |
| Net Profit | 71.86 | 106.22 | 134.28 | 74.99 |
| ↳ QoQ Growth | - | +47.8% | +26.4% | -44.2% |
| EPS | 8.82 | 13.19 | 16.09 | 9.07 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 40.9345 | 40.94 |
| Reserves | 1268.6942 | 1612.63 |
| Borrowings | 8.18 | 35.6 |
| Other Liabilities | 231.45 | 294.79 |
| Total Liabilities | 1549.2611 | 1983.96 |
| Fixed Assets | 570.3891 | 633.32 |
| CWIP | 130.284 | 332.32 |
| Investments | 0.2 | 0.2 |
| Other Assets | 848.39 | 1018.12 |
| Total Assets | 1549.2611 | 1983.96 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 118.3427 |
| Cash from Investing Activity | -223.9432 |
| Cash from Financing Activity | 261.1204 |
| Net Cash Flow | 155.5199 |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 32.66% | 32.66% | 32.66% | 32.66% |
| FIIs % | 16.85% | 16.67% | 19.48% | 21.61% |
| DIIs % | 22.59% | 21.7% | 19.6% | 19.56% |
| Public % | 22.79% | 23.53% | 23.21% | 21.72% |
| No. of Shareholders | 1,08,664 | 1,10,363 | 1,12,939 | 1,25,569 |
Major Shareholders (>1%)
- Nareshkumar Ramjibhai PatelPromoter and Promoter Group17.69%
- Vaghasia Chetankumar ChhaganlalPromoter and Promoter Group14.97%
- Government Pension Fund GlobalPublic Shareholding3.54%
- Kotak Mahindra Trustee Co Ltd A/c Kotak Multicap FundPublic Shareholding3.53%
As of 2026-06-30View all shareholders →